modelLenalidomide
Extends from Pharmacolibrary.Drugs.ATC.L.L04AX04.
Information
| name: | Lenalidomide | |
| ATC code: | L04AX04 | route: | oral |
| compartments: | 1 | |
| dosage: | 25 | mg |
| volume of distribution: | 75 | L |
| clearance: | 8.6 | L/h |
| other parameters in model implementation | ||
Lenalidomide is an immunomodulatory drug used primarily for the treatment of multiple myeloma and certain myelodysplastic syndromes. It is an oral derivative of thalidomide and is currently approved for use in several countries for these indications.
Pharmacokinetics
Pharmacokinetic parameters observed in adult patients (both sexes) with multiple myeloma after a single oral dose under fasting conditions.
References
Hughes, JH, et al., & Foster, DJR (2019). Population pharmacokinetics of lenalidomide in patients with B-cell malignancies. British journal of clinical pharmacology 85(5) 924–934. DOI:10.1111/bcp.13873 PUBMED:https://pubmed.ncbi.nlm.nih.gov/30672004
Chen, N, et al., & Palmisano, M (2017). Clinical Pharmacokinetics and Pharmacodynamics of Lenalidomide. Clinical pharmacokinetics 56(2) 139–152. DOI:10.1007/s40262-016-0432-1 PUBMED:https://pubmed.ncbi.nlm.nih.gov/27351179
O'Donnell, EK, et al., & Raje, NS (2018). A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma. British journal of haematology 182(2) 222–230. DOI:10.1111/bjh.15261 PUBMED:https://pubmed.ncbi.nlm.nih.gov/29740809
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)